Mir-21 is a New Biomarker for Personalized Oncology

Lung cancer is the most common cause of death among all cancers and despite advances in combination chemotherapies, the prognosis of lung cancer is still dismal. miRNAs are a class of endogenous non‑coding RNAs, that are inhibit gene expression at the post‑transcriptional level. The levels of individual miRNAs vary significantly between tissues, developmental stages and physiological processes. The tissue‑ and disease‑specific expression patterns of miRNAs indicate their potential as diagnostic and prognostic cancer biomarkers and therapeutic tools and helpful in matching targeted therapies with patients. A total of 40 newly diagnosed primary lung cancer patients and 40 cancer-free subjects were enrolled in this study. All the patients were classified according to the 7th International Union Against Cancer tumor, lymph node, and metastasis staging system. Total RNA was extracted from blood using TRIzol reagent according to the manufacturer’s protocol. Quantitative real-time PCR (qRT-PCR) was performed. The special primer was used to synthesize miR-21 cDNA. The relative expression of genes was calculated using the 2−ΔΔCt method from an independent experiment, and HGPRT was used to normalize mRNA. In the present study, we found that miR-21P was frequently up-regulated in lung cancer patients than control group and also the increasing miR-21p expression was closely related to advanced stage and lymph node metastasis of NSCLC.

کلیدواژه ها:

Biomarker ، Personalized Oncology ، Lung Cancer ، MicroRNA